Gary Nachman
Stock Analyst at BMO Capital
(3.43)
# 950
Out of 4,711 analysts
100
Total ratings
57.35%
Success rate
1.49%
Average return
Main Sectors:
Stocks Rated by Gary Nachman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SDGR Schrödinger | Maintains: Outperform | $25 → $28 | $19.44 | +44.03% | 5 | Nov 13, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $275 → $298 | $245.44 | +21.41% | 7 | Nov 1, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Outperform | $37 | $32.63 | +13.39% | 1 | Sep 27, 2024 | |
| ACHV Achieve Life Sciences | Initiates: Strong Buy | $20 | $3.69 | +442.01% | 1 | Sep 27, 2024 | |
| PCRX Pacira BioSciences | Maintains: Outperform | $41 → $37 | $18.98 | +94.94% | 13 | Jul 31, 2024 | |
| BLCO Bausch + Lomb | Initiates: Outperform | $19 | $18.00 | +5.56% | 1 | Jul 10, 2024 | |
| AMGN Amgen | Reinstates: Market Perform | n/a | $263.38 | - | 1 | Mar 28, 2024 | |
| SRRK Scholar Rock Holding | Initiates: Strong Buy | $30 | $44.78 | -33.01% | 5 | Mar 28, 2024 | |
| AQST Aquestive Therapeutics | Initiates: Outperform | $7 | $3.65 | +91.78% | 1 | Mar 28, 2024 | |
| VERU Veru Inc. | Initiates: Outperform | $3 | $0.65 | +362.18% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $181 → $189 | $175.58 | +7.64% | 13 | Feb 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $122.97 | - | 11 | Sep 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $4 | $7.78 | -48.59% | 5 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $30 | $7.45 | +302.68% | 4 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $67 | $35.63 | +88.04% | 2 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $32 | $2.85 | +1,022.81% | 1 | Feb 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $16 → $14 | $12.52 | +11.82% | 2 | Feb 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $5 | $0.42 | +1,090.19% | 4 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $43 → $40 | $5.61 | +613.01% | 8 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $11 → $10 | $22.09 | -54.73% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $30 | $17.09 | +75.54% | 2 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $810 → $750 | $3.22 | +23,191.93% | 2 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $8 | $7.47 | +7.10% | 2 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $20 → $21 | $39.14 | -46.35% | 5 | May 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $14 | $3.39 | +312.98% | 2 | Jun 14, 2018 |
Schrödinger
Nov 13, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $19.44
Upside: +44.03%
Alnylam Pharmaceuticals
Nov 1, 2024
Maintains: Outperform
Price Target: $275 → $298
Current: $245.44
Upside: +21.41%
LENZ Therapeutics
Sep 27, 2024
Initiates: Outperform
Price Target: $37
Current: $32.63
Upside: +13.39%
Achieve Life Sciences
Sep 27, 2024
Initiates: Strong Buy
Price Target: $20
Current: $3.69
Upside: +442.01%
Pacira BioSciences
Jul 31, 2024
Maintains: Outperform
Price Target: $41 → $37
Current: $18.98
Upside: +94.94%
Bausch + Lomb
Jul 10, 2024
Initiates: Outperform
Price Target: $19
Current: $18.00
Upside: +5.56%
Amgen
Mar 28, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $263.38
Upside: -
Scholar Rock Holding
Mar 28, 2024
Initiates: Strong Buy
Price Target: $30
Current: $44.78
Upside: -33.01%
Aquestive Therapeutics
Mar 28, 2024
Initiates: Outperform
Price Target: $7
Current: $3.65
Upside: +91.78%
Veru Inc.
Mar 28, 2024
Initiates: Outperform
Price Target: $3
Current: $0.65
Upside: +362.18%
Feb 6, 2024
Maintains: Outperform
Price Target: $181 → $189
Current: $175.58
Upside: +7.64%
Sep 29, 2023
Initiates: Market Perform
Price Target: n/a
Current: $122.97
Upside: -
Mar 3, 2023
Maintains: Market Perform
Price Target: $5 → $4
Current: $7.78
Upside: -48.59%
Mar 1, 2023
Maintains: Outperform
Price Target: $35 → $30
Current: $7.45
Upside: +302.68%
Feb 23, 2023
Maintains: Outperform
Price Target: $70 → $67
Current: $35.63
Upside: +88.04%
Feb 22, 2023
Maintains: Outperform
Price Target: $40 → $32
Current: $2.85
Upside: +1,022.81%
Feb 17, 2023
Downgrades: Market Perform
Price Target: $16 → $14
Current: $12.52
Upside: +11.82%
Nov 14, 2022
Maintains: Outperform
Price Target: $6 → $5
Current: $0.42
Upside: +1,090.19%
Nov 9, 2022
Maintains: Market Perform
Price Target: $43 → $40
Current: $5.61
Upside: +613.01%
Nov 7, 2022
Maintains: Market Perform
Price Target: $11 → $10
Current: $22.09
Upside: -54.73%
Nov 4, 2022
Maintains: Outperform
Price Target: $40 → $30
Current: $17.09
Upside: +75.54%
Aug 11, 2022
Maintains: Outperform
Price Target: $810 → $750
Current: $3.22
Upside: +23,191.93%
Aug 10, 2022
Maintains: Market Perform
Price Target: $15 → $8
Current: $7.47
Upside: +7.10%
May 11, 2020
Maintains: Market Perform
Price Target: $20 → $21
Current: $39.14
Upside: -46.35%
Jun 14, 2018
Maintains: Outperform
Price Target: $24 → $14
Current: $3.39
Upside: +312.98%